What is the Historic and Current Scenario of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market has seen considerable growth due to a variety of factors.
•In recent times, there has been a slight expansion in the anti-vascular endothelial growth factor therapeutics market size. Projections suggest growth from $12.2 billion in 2024 to $12.31 billion in 2025, indicating a compound annual growth rate (CAGR) of 1.0%.
Factors contributing to this growth during the historical period include an increase in age-related macular degeneration, a rise in diabetic retinopathy cases, advancements in diagnosing retinal disease, clinical success and efficacy, and a transition to outpatient treatment.
What are the Forecasted Growth and Key Factors of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for anti-vascular endothelial growth factor therapeutics is predicted to steadily expand in the following few years. It is poised to reach "$13.49 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 2.3%.
The expansion during the anticipated period is linked to factors like the rising aging populace and eye-related disorders, broader usage in treating retinal diseases, the advent of next gene therapeutics, focus on early stage intervention, worldwide health plans, and better access to treatment. Mainstream trends for the projected period encompass the escalated use in cancer care, concentration on combined therapies for ocular conditions, examination of bio-similar variants, studies into resistance pathways, and amalgamation with imaging technology.
What Are the Critical Driver Fuelling the Anti-Vascular Endothelial Growth Factor Therapeutics Market's Growth?
The escalating occurrence of eye-related illnesses is projected to fuel the expansion of the anti-vascular endothelial growth factor therapeutics market. The term 'prevalence of ophthalmic diseases' implies the percentage or count of people in a particular population who are diagnosed with or display certain eye diseases or conditions. Anti-vascular endothelial growth factor (VEGF) treatments aid in decreasing eye disease prevalence by effectively curing issues like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For example, the World Health Organization, a Swiss-based global public health entity, reported in October 2022 that around 2.2 billion people worldwide have either near or distance vision difficulties, and 1 billion individuals suffer from near or distance vision impairment. Also, out of these, 88.4 million are grappling with refractive error, 94 million are suffering from cataracts, 8 million from age-related macular degeneration, and approximately 3.9 million from diabetic retinopathy. Consequently, the rising prevalence of eye-related illnesses is stimulating the anti-vascular endothelial growth factor therapeutics market's development.
How Is the Anti-Vascular Endothelial Growth Factor Therapeutics Market segmented?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Pre-Book The Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The trend of advancements in therapeutic treatments is gaining traction in the anti-vascular endothelial growth factor therapeutics market. Firms in this market are leveraging these cutting-edge therapies to maintain their competitive edge. For example, in May 2022, Ashvattha Therapeutics Inc., a US clinical-stage biopharmaceutical enterprise, published phase 1 safety data for healthy subjects concerning subcutaneous anti-VEGF therapy for wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. D-4517.2 therapy, a pioneering treatment created to fulfill the unaddressed needs of DME patients, is currently under development for self-administration via an autoinjector. This D-4517.2 autoinjector empowers patients to self-administer their medication monthly in the comfort and familiarity of their own homes.
Who Are the Key Players in the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include:
• F. Hoffmann-La Roche AG
• Biogen Inc.
• Pfizer Inc.
• Coherus BioSciences Inc.
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Viatris Inc.
• Xbrane Biopharma AB
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• Genentech Inc
• Allergan Inc.
• Novartis AG
• kyowa Kirin Co. Ltd.
• Amgen Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• Johnson & Johnson Private Limited
• Sanofi S.A.
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals Incorporated
• Alexion Pharmaceuticals Inc.
What Is The Most Dominant Region In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
